Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
22
PRQR Quote, Financials, Valuation and Earnings
Last price:
$1.59
Seasonality move
:
-10.69%
Day range:
$1.53 - $1.60
52-week range:
$1.07 - $3.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.62x
P/B ratio:
2.50x
Volume:
279.9K
Avg. volume:
386.3K
1-year change:
-33.75%
Market cap:
$167.5M
Revenue:
$20.4M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$6.1M | -$0.17 | 17.05% | -55.96% | $8.88 |
|
ARGX
argenx SE
|
$1.3B | $6.19 | 87.13% | 205.62% | $1,031.68 |
|
NAMS
NewAmsterdam Pharma Co. NV
|
$2.9M | -$0.43 | -60.56% | -48.71% | $48.95 |
|
PHAR
Pharming Group NV
|
$106.1M | $0.01 | 17.76% | -100% | $31.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.72 | -- | -15.87% | $46.30 |
|
QURE
uniQure NV
|
$5.6M | -$0.93 | 339.4% | -13.99% | $53.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$1.59 | $8.88 | $167.5M | -- | $0.00 | 0% | 9.62x |
|
ARGX
argenx SE
|
$771.53 | $1,031.68 | $47.7B | 42.59x | $0.00 | 0% | 16.45x |
|
NAMS
NewAmsterdam Pharma Co. NV
|
$34.28 | $48.95 | $3.9B | -- | $0.00 | 0% | 178.26x |
|
PHAR
Pharming Group NV
|
$16.37 | $31.00 | $1.1B | 1,144.76x | $0.00 | 0% | 3.08x |
|
PHVS
Pharvaris NV
|
$28.00 | $46.30 | $1.8B | -- | $0.00 | 0% | -- |
|
QURE
uniQure NV
|
$17.12 | $53.52 | $1.1B | -- | $0.00 | 0% | 58.48x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.348 | 7.64% | 3.23x |
|
ARGX
argenx SE
|
-- | 0.022 | -- | 4.92x |
|
NAMS
NewAmsterdam Pharma Co. NV
|
0.03% | 1.199 | 0.01% | 7.43x |
|
PHAR
Pharming Group NV
|
33.1% | 0.932 | 13.18% | 2.39x |
|
PHVS
Pharvaris NV
|
0.19% | -0.126 | 0.04% | 12.56x |
|
QURE
uniQure NV
|
69.92% | 7.217 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
NAMS
NewAmsterdam Pharma Co. NV
|
-$27K | -$66M | -27.35% | -27.36% | -206187.5% | -$41M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PHVS
Pharvaris NV
|
-$122.9K | -$46.3M | -62.86% | -63% | -- | -$38.2M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
ProQR Therapeutics NV vs. Competitors
-
Which has Higher Returns PRQR or ARGX?
argenx SE has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 25.88%. ProQR Therapeutics NV's return on equity of -67.34% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About PRQR or ARGX?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 458.18%. On the other hand argenx SE has an analysts' consensus of $1,031.68 which suggests that it could grow by 33.72%. Given that ProQR Therapeutics NV has higher upside potential than argenx SE, analysts believe ProQR Therapeutics NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 ARGXargenx SE15 1 0 -
Is PRQR or ARGX More Risky?
ProQR Therapeutics NV has a beta of 0.200, which suggesting that the stock is 79.991% less volatile than S&P 500. In comparison argenx SE has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.596%.
-
Which is a Better Dividend Stock PRQR or ARGX?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or ARGX?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than argenx SE quarterly revenues of $948M. ProQR Therapeutics NV's net income of -$12.9M is lower than argenx SE's net income of $245.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 42.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 9.62x versus 16.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M ARGXargenx SE16.45x 42.59x $948M $245.4M
-
Which has Higher Returns PRQR or NAMS?
NewAmsterdam Pharma Co. NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -234134.38%. ProQR Therapeutics NV's return on equity of -67.34% beat NewAmsterdam Pharma Co. NV's return on equity of -27.36%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M NAMSNewAmsterdam Pharma Co. NV-84.38% -$0.65 $683.6M -
What do Analysts Say About PRQR or NAMS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 458.18%. On the other hand NewAmsterdam Pharma Co. NV has an analysts' consensus of $48.95 which suggests that it could grow by 42.81%. Given that ProQR Therapeutics NV has higher upside potential than NewAmsterdam Pharma Co. NV, analysts believe ProQR Therapeutics NV is more attractive than NewAmsterdam Pharma Co. NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 NAMSNewAmsterdam Pharma Co. NV10 1 0 -
Is PRQR or NAMS More Risky?
ProQR Therapeutics NV has a beta of 0.200, which suggesting that the stock is 79.991% less volatile than S&P 500. In comparison NewAmsterdam Pharma Co. NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or NAMS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NewAmsterdam Pharma Co. NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. NewAmsterdam Pharma Co. NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or NAMS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are larger than NewAmsterdam Pharma Co. NV quarterly revenues of $32K. ProQR Therapeutics NV's net income of -$12.9M is higher than NewAmsterdam Pharma Co. NV's net income of -$74.9M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while NewAmsterdam Pharma Co. NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 9.62x versus 178.26x for NewAmsterdam Pharma Co. NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M NAMSNewAmsterdam Pharma Co. NV178.26x -- $32K -$74.9M
-
Which has Higher Returns PRQR or PHAR?
Pharming Group NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of 7.71%. ProQR Therapeutics NV's return on equity of -67.34% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About PRQR or PHAR?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 458.18%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 89.37%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group NV, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHARPharming Group NV3 0 0 -
Is PRQR or PHAR More Risky?
ProQR Therapeutics NV has a beta of 0.200, which suggesting that the stock is 79.991% less volatile than S&P 500. In comparison Pharming Group NV has a beta of -0.009, suggesting its less volatile than the S&P 500 by 100.89%.
-
Which is a Better Dividend Stock PRQR or PHAR?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHAR?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than Pharming Group NV quarterly revenues of $96.9M. ProQR Therapeutics NV's net income of -$12.9M is lower than Pharming Group NV's net income of $7.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,144.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 9.62x versus 3.08x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M PHARPharming Group NV3.08x 1,144.76x $96.9M $7.5M
-
Which has Higher Returns PRQR or PHVS?
Pharvaris NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of --. ProQR Therapeutics NV's return on equity of -67.34% beat Pharvaris NV's return on equity of -63%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M PHVSPharvaris NV-- -$0.70 $367.6M -
What do Analysts Say About PRQR or PHVS?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 458.18%. On the other hand Pharvaris NV has an analysts' consensus of $46.30 which suggests that it could grow by 65.34%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 PHVSPharvaris NV8 1 0 -
Is PRQR or PHVS More Risky?
ProQR Therapeutics NV has a beta of 0.200, which suggesting that the stock is 79.991% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRQR or PHVS?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or PHVS?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are larger than Pharvaris NV quarterly revenues of --. ProQR Therapeutics NV's net income of -$12.9M is higher than Pharvaris NV's net income of -$43.4M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 9.62x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M PHVSPharvaris NV-- -- -- -$43.4M
-
Which has Higher Returns PRQR or QURE?
uniQure NV has a net margin of -381.88% compared to ProQR Therapeutics NV's net margin of -2175.87%. ProQR Therapeutics NV's return on equity of -67.34% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PRQR or QURE?
ProQR Therapeutics NV has a consensus price target of $8.88, signalling upside risk potential of 458.18%. On the other hand uniQure NV has an analysts' consensus of $53.52 which suggests that it could grow by 212.7%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings PRQRProQR Therapeutics NV7 0 0 QUREuniQure NV9 4 0 -
Is PRQR or QURE More Risky?
ProQR Therapeutics NV has a beta of 0.200, which suggesting that the stock is 79.991% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.669%.
-
Which is a Better Dividend Stock PRQR or QURE?
ProQR Therapeutics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProQR Therapeutics NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRQR or QURE?
ProQR Therapeutics NV quarterly revenues are $3.4M, which are smaller than uniQure NV quarterly revenues of $3.7M. ProQR Therapeutics NV's net income of -$12.9M is higher than uniQure NV's net income of -$80.5M. Notably, ProQR Therapeutics NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProQR Therapeutics NV is 9.62x versus 58.48x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRQRProQR Therapeutics NV9.62x -- $3.4M -$12.9M QUREuniQure NV58.48x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
